The histopathological evaluation of human breast cancers in correlation with estrogen receptor values

A detailed histopathological review of 140 primary breast cancers analyzed for estrogen receptor protein (ERP) was carried out and a variety of morphological features correlated with ERP results. ERP in cytosols was incubated with [3H]estradiol in the presence and absence of cold estradiol and assayed by agargel electrophoresis. Tumors binding > 10 fmol estradiol/mg tissue protein were classified as receptor‐positive. Seventy‐seven percent of the 116 infiltrating duct carcinomas were ERP‐positive. The well‐differentiated tumors of this group had a higher incidence of ERP‐positivity than the poorly differentiated ones. The ten predominantly or exclusively intraductal carcinomas and the seven medullary tumors were less frequently positive than the main group of infiltrating ductal cancers. The three colloid, two tubular, and two lobular carcinomas in this series were all ERP‐positive. When receptor measurements are evaluated, consideration should be given to the degree of differentiation and the histological type of tumor, in addition to other factors known to influence receptor levels such as menopausal status and seasonal variation.

[1]  P. Furmanski,et al.  Prognostic value of estrogen receptor determinations in patients with breast cancer. , 1978, Cancer research.

[2]  Meyer Js,et al.  Subpopulations of breast carcinoma defined by S-phase fraction, morphology, and estrogen receptor content. , 1978 .

[3]  P. Carstens.  Tubular carcinoma of the breast. A study of frequency. , 1978, American journal of clinical pathology.

[4]  S. Lee.  Cytochemical study of estrogen receptor in human mammary cancer. , 1978, American journal of clinical pathology.

[5]  J. Gustafsson,et al.  Effect of antiestrogen therapy on human mammary carcinomas with different estrogen receptor contents. , 1978, European journal of cancer.

[6]  A. Miyake,et al.  The time course change after castration in short-loop negative feedback control of LH by HCG in women. , 1978, Acta endocrinologica.

[7]  A. C. Carter,et al.  Immunofluorescent detection of estrogen receptors in breast cancer. Comparison with dextran‐coated charcoal and sucrose gradient assays , 1978, Cancer.

[8]  W. Kraybill,et al.  The use of antiestrogens tamoxifen and nafoxidine in the treatment of human breast cancer in correlation with estrogen receptor values. A phase II study , 1978, Cancer.

[9]  W. Fletcher,et al.  The prognostic significance of estrogen receptors in human breast cancer. , 1978, American journal of surgery.

[10]  J. Meyer,et al.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication , 1977, Cancer.

[11]  W. Sierralta,et al.  A proposal for assessment of hormone sensitivity and consequent endocrine therapy of breast cancer. , 1977, European journal of cancer.

[12]  W. McGuire,et al.  Current status of estrogen and progesterone receptors in breast cancer , 1977, Cancer.

[13]  R. Sylvester,et al.  Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer , 1977, Cancer.

[14]  H. Jacobson,et al.  Ovarian-independent fluctuations of estradiol receptor levels in mammalian tissues , 1976, Molecular and Cellular Endocrinology.

[15]  P. Jungblut,et al.  Oestradiol- and dihydrotestosterone receptors in normal and neoplastic human mammary tissue. , 1976, Acta endocrinologica.

[16]  M. Black,et al.  Prognosis in breast cancer utilizing histologic characteristics of the primary tumor , 1975 .

[17]  J. Pasqualini.  Receptors in human breast cancer: (Edited by W. L. McGuire, P. P. Carbone and E. P. Vollmer). North-Holland Publishing Company, Amsterdam (1975), 284 pp , 1975 .

[18]  E. Jensen.  Estrogen receptors in hormone-dependent breast cancers. , 1975, Cancer research.

[19]  J. Urban,et al.  Pathological review of breast lesions analyzed for estrogen receptor protein. , 1975, Cancer research.

[20]  G. Trams,et al.  Steroid hormone receptors in human breast cancer and the clinical significance. , 1975, Journal of steroid biochemistry.

[21]  E. Jensen.  Editorial: Some newer endocrine aspects of breast cancer. , 1974, The New England journal of medicine.

[22]  L. Terenius,et al.  Malignant and benign human mammary disease: Estrogen binding in relation to clinical data , 1974, Cancer.

[23]  A. Chitale,et al.  Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast , 1973, Cancer.

[24]  J. Wittliff,et al.  Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. , 1972, Cancer research.

[25]  R. Wagner.  Characterization and assay of steroid hormone receptors and steroid-binding serum proteins by agargel electrophoresis at low temperature. , 1972, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[26]  G. Farrer-brown,et al.  Oestradiol Receptors in Carcinoma and Benign Disease of the Breast: An In Vitro Assay , 1971, British Journal of Cancer.

[27]  H. Bloom,et al.  Host Resistance and Survival in Carcinoma of Breast: A Study of 104 Cases of Medullary Carcinoma in a Series of 1,411 Cases of Breast Cancer Followed for 20 years* , 1970, British medical journal.

[28]  N. Warner.  Lobular carcinoma of the breast , 1969, Cancer.

[29]  R. Hutter,et al.  In situ lobular carcinoma. A prospective follow-up study indicating cumulative patient risks. , 1967, JAMA.

[30]  N. Kouchoukos,et al.  Prediction of axillary nodal metastases from the morphology of primary mammary carcinomas. Guide to operative therapy , 1967, Cancer.

[31]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[32]  I. Bross,et al.  The significance of delay in relation to prognosis of patients with primary operable breast cancer , 1957, Cancer.

[33]  Palmer O. Johnson,et al.  Statistical Methods in Research , 1949 .

[34]  F. W. Foote,et al.  The relatively favorable prognosis of medullary carcinoma of the breast , 1949, Cancer.